Entero Therapeutics, Inc.
ENTO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $3 | $0 | $0 | $0 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $85 | $83 | $83 | $83 |
| Total Curr. Assets | $88 | $83 | $83 | $83 |
| Property Plant & Equip (Net) | $0 | $0 | $0 | $0 |
| Goodwill | $26 | $2 | $2 | $2 |
| Intangibles | $22 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $0 | $0 |
| Total NC Assets | $48 | $2 | $2 | $2 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $135 | $85 | $85 | $85 |
| Liabilities | – | – | – | – |
| Payables | $5 | $3 | $3 | $3 |
| Short-Term Debt | $1 | $1 | $1 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $28 | $26 | $25 | $25 |
| Total Curr. Liab. | $34 | $30 | $29 | $28 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $12 | $0 | $0 | $0 |
| Total NC Liab. | $12 | $0 | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $46 | $30 | $29 | $28 |
| Equity | – | – | – | – |
| Pref Stock | $62 | $62 | $62 | $62 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$206 | -$205 | -$204 | -$202 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $228 | $198 | $198 | $199 |
| Total Equity | $84 | $55 | $56 | $58 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $5 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $135 | $85 | $85 | $85 |
| Net Debt | -$2 | $1 | $1 | -$0 |